LTFS
PHAS

Ladenburg Thalmann Financial Services’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$12K Hold
2,000
– – ﹤0.01% 4425
2019
Q3 		$8K Buy
+2,000
New +$15.9K ﹤0.01% 4513

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PHAS Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) position steady in Q4 2019 at 2,000 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4425.

Ladenburg Thalmann Financial Services first reported a position in PHAS in Q3 2019 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 2,000 shares of PhaseBio Pharmaceuticals, Inc. Common Stock worth $12K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its PhaseBio Pharmaceuticals, Inc. Common Stock share count unchanged in Q4 2019.
  • PhaseBio Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4425 holding.
  • Ladenburg Thalmann Financial Services first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.